IBRX — ImmunityBio, Inc. catalysts
Next verified catalyst
2027-03-01 — A Study to Examine Anktiva for the Treatment of COVID-19. · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2027-03 (month) in 4mo
ESTIMATED |
READOUT
A Study to Examine Anktiva for the Treatment of COVID-19.
Phase 2 · Long COVID, Long COVID Syndrome |
IBRX ImmunityBio, Inc. | Anktiva |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|